← Back to headlines
Amgen announces positive late-stage results for subcutaneous Tepezza
Amgen reported positive late-stage clinical trial results for its subcutaneous drug, Tepezza, indicating promising developments for its efficacy.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
